Trials / Terminated
TerminatedNCT02231658
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide | |
| DRUG | Lixisenatide |
Timeline
- Start date
- 2015-07-16
- Primary completion
- 2018-07-23
- Completion
- 2018-07-23
- First posted
- 2014-09-04
- Last updated
- 2018-10-17
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02231658. Inclusion in this directory is not an endorsement.